Quantcast
Last updated on April 17, 2014 at 15:37 EDT

Latest Natalizumab Stories

2013-07-14 23:00:54

Transparency Market Research add new "Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018" market research report to its report store. Browse the report: visit http://www.transparencymarketresearch.com/multiple-sclerosis-drugs.html Albany, New York (PRWEB) July 14, 2013 Multiple sclerosis (MS) is an inflammation of fatty myelin sheaths around the axons of the brain and spinal cord. MS tends to affect the ability of...

2013-05-30 12:27:17

However, Aubagio's Prescriber Base Continues to Lag Behind That of Novartis's Gilenya at Same Stage of Product Launch, According to a New Report from BioTrends Research Group EXTON, Pa., May 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that over half of surveyed neurologists have prescribed Aubagio, the second oral disease-modifying agent (DMA) marketed for multiple sclerosis...

2013-04-10 23:02:54

According to Ironclad Integrity Ltd MS natural treatments have become all the rage lately as these promise effective results, no side-effects and lower health care bills. The company has released via http://www.SclerosisTreatment.com reviews and price analysis for the most popular MS alternative therapies. Denver, Colorado (PRWEB) April 10, 2013 Health organizations estimate there are about 400,000 Multiple Sclerosis patients in the United States today, but that number is certainly higher...

2013-04-08 08:31:12

An Increased Effect in Preventing Sustained Disability Progression is One of the Greatest Unmet Needs in RR-MS, According to a New Report from Decision Resources BURLINGTON, Mass., April 8, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. neurologists indicated that they would prescribe Biogen Idec's Tecfidera to 20 percent of their patients with relapsing-remitting...

2013-04-04 08:29:31

Studies find prior authorization programs are associated with increased quality of care and cost effectiveness; 30- versus 90- day supply claims reduce specialty medication waste SAN DIEGO, April 4, 2013 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager, will be presenting three new studies at the Academy of Managed Care Pharmacy (AMCP)'s 25(th) Annual meeting & Expo in San Diego today. Studies concluded that UM programs may increase the quality of...

2013-03-11 13:22:56

The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. The study examined 319 people with MS who were treated with...

2013-03-10 23:01:33

The http://www.SclerosisTreatment.com website, a division of Ironclad Integrity Ltd., reveals a new therapy based on plants, vitamins and correct nutrition to reduce fatigue, pain and other MS symptoms instead of drug intake. Denver, Colorado (PRWEB) March 10, 2013 According to http://www.Sclerosistreatment.com for the 2.5 million MS patients worldwide, the lack of a permanent cure for their condition is frustrating and puzzling. Conventional therapies to treat Multiple Sclerosis are based...

2013-03-10 16:20:35

SAN DIEGO, March 10, 2013 /PRNewswire-USNewswire/ -- The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. The study...

2013-03-06 08:26:20

This announcement does not constitute an announcement of a firm intention to make an offer under the Irish Takeover Rules NEW YORK, March 6, 2013 /PRNewswire/ -- RP Management, LLC ("Royalty Pharma") remains committed to acquiring Elan (NYSE: ELN) on the terms set out in the Proposal Announcement of February 25, 2013, but continues to be disappointed that the Board of Elan has not engaged in discussions. Royalty Pharma is ready and able to move quickly to implement an offer and...

2013-01-16 08:24:44

EXTON, Penn., Jan. 16, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the recent commercial availability of Genzyme's Aubagio, the second oral disease-modifying agent (DMA) to the market following Novartis's launch of Gilenya in late 2010, is top of mind for few neurologists as a change in the management or treatment of their multiple sclerosis (MS) patients. Instead, data from the...